
Menstrual tracking app data in the wrong hands ‘could result in risks to job prospects, workplace monitoring'
Menstrual cycle tracking apps could jeopardize the safety and privacy of users, a new report warns, with personal data commonly sold to companies.
The stakes are high since period tracking apps have soared in popularity and become ubiquitous amid limited access to information, a lack of research and stigma about menstruation health.
A 2024 study estimates that global downloads for the three most popular menstruation cycle tracking apps surpassed 250 million.
Those who use apps that track periods often don't consider the data 'intimate' or commercially valuable, and need more protections from potential abuse of their personal information, according to the report released Tuesday, by The Minderoo Centre for Technology and Democracy (MCTD), an independent team of academic researchers at the University of Cambridge in the U.K. would split up this long list of proper names
'Menstrual tracking applications turn personal health information into data points to be collected, analyzed, and sold,' according to the report.
Data sold to companies, advertisers
The study noted the apps pose 'significant risks' for users as femtech has become a 'lucrative trend' and the user data is 'extremely valuable' for a wide range of companies, from those that developed the app to big tech firms and advertising industries.
Femtech refers to digital products, services or technologies promoting women's health and wellbeing, with period-tracking apps making up 50 per cent of the US$22 billion market in 2020.
'People vastly underestimate the commercial value of menstrual data and the extent to which it can provide insights into their political preferences, health issues, or reproductive choices,' researchers wrote.
The apps offer a way for users to track daily information on anything related to their menstrual health, such as menstrual cycles, predictions on periods, premenstrual syndrome (PMS), ovulation and fertility.
Security and privacy risks
To add to the concerns, researchers say the apps also pose risks to data security and privacy, noting it's widely used in the online advertising industry.
'Self-tracking data has been used to police people's reproductive choices, to undermine a user's testimony in court, and it can lead to increased vulnerability in intimate relationships, partner violence, risks to job prospects via employer access to CTA (cycle tracking application) data, workplace monitoring, or possible health insurance discrimination,' according to the report.
Meanwhile, the report also referred to 'severe security risks,' noting an example in the U.K. where period tracker data was used to charge women for illegally accessing abortion services.
Are period apps accurate?
The study notes many medical studies showed that the apps 'fail to accurately calculate cycle length or ovulation windows' and additional data from people is often not used to improve predictions. Rather, researchers say the information is 'predominantly a source of value' for the companies.
'With most apps providing no or very little information on how predictions are made, a 2023 study found that some users were encouraged to track more data to fine-tune their predictions and train an imagined algorithm,' it wrote.
While users commonly turn to the apps for help them conceive or prevent getting pregnant, people with irregular cycles or conditions such as poly-cystic ovary syndrome, endometriosis, or premenstrual dysphoric disorder may also use the apps to try to understand their medical issues. Many people use the apps to track their emotions and bodily functions as well.
Recommendations
The report recommends improving health care for and incentivising research on menstrual and reproductive health, such as through cycle tracking companies and research institutes working together. It encourages schools and organizations to help raise awareness about menstrual tracking for all ages.
Additionally, it recommends alternatives, such as public bodies developing apps that are 'trustworthy' and collect data in a 'responsible way.'
The report also calls for stricter regulation of menstrual tracking data as 'sensitive health information' in the United States and tighter enforcement of existing regulations in the U.K. and European Union. It suggests improving security through 'consent options,' clear and accessible privacy policies, and prioritizing data privacy and security in the app design. Apps could be more 'transparent' by providing clear information on how tracking data is used to make predictions, with interface options for those who cannot or do not want to become pregnant.
The report notes that not all women menstruate and not everyone with menstrual cycles is a woman. For instance, it wrote that children and teenagers have periods, trans men can menstruate and trans women can experience symptoms similar to premenstrual syndrome (PMS). Most apps are designed for straight cis women who want to get pregnant, it added.
David Young, a privacy and regulatory law expert in Toronto, told CTVNews.ca in a video interview Monday that Canada's Personal Information Protection and Electronic Documents Act already follows the report's recommendations, though the law is 'not always enforced.'
According to Canada's federal privacy law, an organization must not require individuals to consent to the collection, use or disclosure of their information beyond 'explicitly specified, and legitimate purposes.'
'Assuming those specific and legitimate purposes are the tracking that the individual is seeking by use of the app, then they shouldn't be allowed to also require, as a condition of using the app, that they're going to sell that information to somebody else,' Young said. He noted Canada also faces a problem with companies selling consumers' medical data, including electronic health records.
Young said menstrual-related cycle data is considered 'sensitive personal health information.'
'And that has a very high standard of compliance under any privacy law, meaning that there must be clear ... consent to for whatever uses are going to be made of that information. So it's not something you can just use by way of implied consent.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.


CTV News
a day ago
- CTV News
‘I promise you, the funding is coming': Flack on HART Hub's delayed opening
London is being assured that provincial funding to open a Homelessness and Addiction Recovery Treatment (HART) Hub is on its way.


CTV News
2 days ago
- CTV News
Trump administration weighs fate of $9M stockpile of contraceptives feared earmarked for destruction
Irene A Kerkulah, the health officer in charge at the Palala Clinic, looks at an almost-empty shelf at the clinic that once held contraceptives, in Bong County, Friday, June 13, 2025. (AP Photo/Annie Risemberg, File) BRUSSELS — President Donald Trump's administration says it is weighing what to do with family planning supplies stockpiled in Europe that campaigners and two U.S. senators are fighting to save from destruction. Concerns that the Trump administration plans to incinerate the stockpile have angered family planning advocates on both sides of the Atlantic. Campaigners say the supplies stored in a U.S.-funded warehouse in Geel, Belgium, include contraceptive pills, contraceptive implants and IUDs that could spare women in war zones and elsewhere the hardship of unwanted pregnancies. U.S. State Department deputy spokesman Tommy Pigott said Thursday in response to a question about the contraceptives that 'we're still in the process here in terms of determining the way forward.' 'When we have an update, we'll provide it,' he said. Belgium says it has been talking with U.S. diplomats about trying to spare the supplies from destruction, including possibly moving them out of the warehouse. Foreign Ministry spokesperson Florinda Baleci told The Associated Press that she couldn't comment further 'to avoid influencing the outcome of the discussions.' The Trump administration's dismantling of the U.S. Agency for International Development, which managed foreign aid programs, left the supplies' fate uncertain. Pigott didn't detail the types of contraceptives that make up the stockpile. He said some of the supplies, bought by the previous administration, could 'potentially be' drugs designed to induce abortions. Pigott didn't detail how that might impact Trump administration thinking about how to deal with the drugs or the entire stockpile. Costing more than US$9 million and funded by U.S taxpayers, the family planning supplies were intended for women in war zones, refugee camps and elsewhere, according to a bipartisan letter of protest to U.S. Secretary of State Marco Rubio from U.S. senators Jeanne Shaheen, a New Hampshire Democrat, and Alaska Republican Lisa Murkowski. They said destroying the stockpile 'would be a waste of U.S. taxpayer dollars as well as an abdication of U.S. global leadership in preventing unintended pregnancies, unsafe abortions and maternal deaths — key goals of U.S. foreign assistance.' They urged Rubio to allow another country or partner to distribute the contraceptives. Concerns voiced by European campaigners and lawmakers that the supplies could be transported to France for incineration have led to mounting pressure on government officials to intervene and save them. The executive branch of the European Union, through spokesman Guillaume Mercier, said Friday that 'we continue to monitor the situation closely to explore the most effective solutions.' The U.S. branch of family planning aid group MSI Reproductive Choices said it offered to purchase, repackage and distribute the stock at its own expense but 'these efforts were repeatedly rejected.' The group said the supplies included long-acting IUDs, contraceptive implants and pills, and that they have long shelf-lives, extending as far as 2031. Aid group Doctors Without Borders said incineration would be 'an intentionally reckless and harmful act against women and girls everywhere.' Charles Dallara, the grandson of a French former lawmaker who was a contraception pioneer in France, urged President Emmanuel Macron to not let France 'become an accomplice to this scandal.' 'Do not allow France to take part in the destruction of essential health tools for millions of women,' Dallara wrote in an appeal to the French leader. 'We have a moral and historical responsibility.' ___ Leicester reported from Paris. Matthew Lee contributed from Washington, D.C. Lorne Cook And John Leicester, The Associated Press